Financhill
Buy
84

LLY Quote, Financials, Valuation and Earnings

Last price:
$1,069.00
Seasonality move :
3.95%
Day range:
$1,063.00 - $1,083.48
52-week range:
$623.78 - $1,111.99
Dividend yield:
0.56%
P/E ratio:
53.24x
P/S ratio:
16.52x
P/B ratio:
40.49x
Volume:
2.6M
Avg. volume:
3.8M
1-year change:
40.21%
Market cap:
$963.5B
Revenue:
$45B
EPS (TTM):
$20.22

Analysts' Opinion

  • Consensus Rating
    Eli Lilly & Co. has received a consensus rating of Buy. The company's average rating is a Buy based on 18 Buy ratings, 7 Hold ratings, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $1,093.22, Eli Lilly & Co. has an estimated upside of 1.56% from its current price of $1,076.48.
  • Price Target Downside
    According to analysts, the lowest downside price target is $770.00 representing 100% downside risk from its current price of $1,076.48.

Fair Value

  • According to the consensus of 25 analysts, Eli Lilly & Co. has 1.56% upside to fair value with a price target of $1,093.22 per share.

LLY vs. S&P 500

  • Over the past 5 trading days, Eli Lilly & Co. has underperformed the S&P 500 by -0.97% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

  • Eli Lilly & Co. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Eli Lilly & Co. has grown year-over-year revenues for 10 quarters straight. In the most recent quarter Eli Lilly & Co. reported revenues of $17.6B.

Earnings Growth

  • Eli Lilly & Co. has grown year-over-year earnings for 8 quarters straight. In the most recent quarter Eli Lilly & Co. reported earnings per share of $6.21.
Enterprise value:
996.1B
EV / Invested capital:
15.01x
Price / LTM sales:
16.52x
EV / EBIT:
37.75x
EV / Revenue:
16.76x
PEG ratio (5yr expected):
0.44x
EV / Free cash flow:
154.76x
Price / Operating cash flow:
152.48x
Enterprise value / EBITDA:
35.22x
Gross Profit (TTM):
$49.3B
Return On Assets:
20.03%
Net Income Margin (TTM):
30.99%
Return On Equity:
106.26%
Return On Invested Capital:
33.81%
Operating Margin:
47.65%
Trailing 12 Months Fiscal Quarters
Period Ending 2023-09-30 2024-09-30 2025-09-30 2024-09-30 2025-09-30
Income Statement
Revenue $32.1B $40.9B $59.4B $11.4B $17.6B
Gross Profit $25.2B $33.1B $49.3B $9.3B $14.6B
Operating Income $9.4B $14.4B $26.4B $4.4B $8.4B
EBITDA $10.9B $16.1B $28.3B $4.9B $8.9B
Diluted EPS $5.42 $9.14 $20.22 $1.07 $6.21
Period Ending 2021-09-30 2022-09-30 2023-09-30 2024-09-30 2025-09-30
Balance Sheet
Current Assets $17.8B $17.6B $23B $31.4B $62.1B
Total Assets $48.2B $47.5B $57.9B $75.6B $114.9B
Current Liabilities $13.7B $15.7B $22B $24.7B $40.1B
Total Liabilities $40.2B $37.3B $46.6B $61.3B $91.1B
Total Equity $8B $10.2B $11.3B $14.3B $23.9B
Total Debt $17.1B $15.9B $20.2B $31.1B $42.5B
Trailing 12 Months Fiscal Quarters
Period Ending 2023-09-30 2024-09-30 2025-09-30 2024-09-30 2025-09-30
Cash Flow Statement
Cash Flow Operations $6.1B $6B $16.1B $3.7B $8.8B
Cash From Investing -$5.1B -$10.3B -$10.1B -$4B -$3B
Cash From Financing -$1.2B $5B $440.4M $211.3M $531M
Free Cash Flow -$164.9M -$2.3B $6.4B -$458.9M $6B
LLY
Sector
Market Cap
$963.5B
$28.4M
Price % of 52-Week High
96.81%
51.17%
Dividend Yield
0.56%
0%
Shareholder Yield
1.04%
-1.49%
1-Year Price Total Return
40.21%
-16.67%
Beta (5-Year)
0.370
0.518
Dividend yield:
0.56%
Annualized payout:
$5.20
Payout ratio:
24.15%
Growth streak:
10 years

Technicals

8-day SMA
Buy
Level $1,050.00
200-day SMA
Buy
Level $819.05
Bollinger Bands (100)
Buy
Level 715.94 - 987.74
Chaikin Money Flow
Buy
Level 1.5B
20-day SMA
Buy
Level $1,044.78
Relative Strength Index (RSI14)
Buy
Level 64.74
ADX Line
Buy
Level 30.3
Williams %R
Sell
Level -6.5814
50-day SMA
Buy
Level $960.55
MACD (12, 26)
Buy
Level 23.96
25-day Aroon Oscillator
Sell
Level -36
On Balance Volume
Neutral
Level 1.1B

Financial Scores

Buy
Altman Z-Score (Annual)
Level (8.0453)
Sell
CA Score (Annual)
Level (-0.6336)
Sell
Beneish M-Score (Annual)
Level (-2.1773)
Buy
Momentum Score
Level (3)
Buy
Ohlson Score
Level (-0.2314)
Buy
Piotroski F Score (Annual)
Level (7)
Buy
Quality Ratio Score
Level (9)
Buy
Fundamental Score
Level (10)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Stock Forecast FAQ

In the current month, LLY has received 18 Buy ratings 7 Hold ratings, and 0 Sell ratings. The LLY average analyst price target in the past 3 months is $1,093.22.

  • Where Will Eli Lilly & Co. Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Eli Lilly & Co. share price will rise to $1,093.22 per share over the next 12 months.

  • What Do Analysts Say About Eli Lilly & Co.?

    Analysts are divided on their view about Eli Lilly & Co. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Eli Lilly & Co. is a Sell and believe this share price will drop from its current level to $770.00.

  • What Is Eli Lilly & Co.'s Price Target?

    The price target for Eli Lilly & Co. over the next 1-year time period is forecast to be $1,093.22 according to 25 Wall Street analysts, 18 of them rate the stock a Buy, 0 rate the stock a Sell, and 7 analysts rate the stock a Hold.

  • Is LLY A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Eli Lilly & Co. is a Buy. 18 of 25 analysts rate the stock a Buy at this time.

  • How Can I Buy Shares Of LLY?

    You can purchase shares of Eli Lilly & Co. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Eli Lilly & Co. shares.

  • What Is The Eli Lilly & Co. Share Price Today?

    Eli Lilly & Co. was last trading at $1,069.00 per share. This represents the most recent stock quote for Eli Lilly & Co.. Yesterday, Eli Lilly & Co. closed at $1,076.48 per share.

  • How To Buy Eli Lilly & Co. Stock Online?

    In order to purchase Eli Lilly & Co. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is SentinelOne Stock Undervalued?
Is SentinelOne Stock Undervalued?

Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…

Is Broadcom Stock on Sale?
Is Broadcom Stock on Sale?

Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…

Is Bloom Energy The Best Stock to Buy Now?
Is Bloom Energy The Best Stock to Buy Now?

Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…

Stock Ideas

Buy
55
Is NVDA Stock a Buy?

Market Cap: $4.5T
P/E Ratio: 63x

Buy
53
Is AAPL Stock a Buy?

Market Cap: $4T
P/E Ratio: 36x

Buy
59
Is GOOG Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 39x

Alerts

Buy
60
AAOI alert for Dec 23

Applied Optoelectronics, Inc. [AAOI] is up 3.95% over the past day.

Buy
52
ABVX alert for Dec 23

Abivax SA [ABVX] is down 0.27% over the past day.

Buy
60
ZBIO alert for Dec 23

Zenas BioPharma, Inc. [ZBIO] is up 1.18% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock